Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone Acetonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CNR1 | P21554 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone Acetonide SCHEMBL13234864 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL1692059 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL4002585 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL12323208 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL16393966 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL4448 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL13839748 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL11911289 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL21051778 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL5484214 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | NEKTAR THERAPEUTICS (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | NEKTAR THERAPEUTICS (US) | 2024-06-25 | — | — | US | disclosed |
| US-20210393513-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | REDHILL BIOPHARMA LTD. (IL) | 2021-12-23 | — | — | US | disclosed |
| US-11129794-B2 | Chemically modified small molecules | NEKTAR THERAPEUTICS (US) | 2021-09-28 | — | — | US | disclosed |
| US-20190099363-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | REDHILL BIOPHARMA LTD. (IL) | 2019-04-04 | — | — | US | disclosed |
| US-20170095565-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-20170095565-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-9388104-B2 | Chemically modified small molecules | NEKTAR THERAPEUTICS (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388104-B2 | Chemically modified small molecules | NEKTAR THERAPEUTICS (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150197470-A9 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197470-A9 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140303403-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303403-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120088745-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS | 2012-04-12 | — | — | US | disclosed |
| US-20120088745-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS | 2012-04-12 | — | — | US | disclosed |
| US-8067431-B2 | Chemically modified small molecules | NEKTAR THERAPEUTICS (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067431-B2 | Chemically modified small molecules | NEKTAR THERAPEUTICS (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100210676-A1 | Chemically Modified Small Molecules | NEKTAR THERAPEUTICS | 2010-08-19 | — | — | US | disclosed |
| US-20100210676-A1 | Chemically Modified Small Molecules | NEKTAR THERAPEUTICS | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.